Abstract
Objective. Connective tissue disease-associated interstitial pneumonia (CTD-IP) significantly affects the mortality of patients with CTD. The purpose of the present study is to identify causes and risk factors for death during hospitalization for immunosuppressive treatment of CTD-IP. Methods. A multicenter, retrospective study was conducted that collected data from patients with CTD who had been hospitalized for commencing or intensifying immunosuppressive treatment of CTD-IP using a standardized case report form. Risk factors were identified using the Cox proportional hazard regression model. Results. A total of 322 CTD-IP patients were enrolled with rheumatoid arthritis (n = 84), systemic lupus erythematosus (n = 13), polymyositis (n = 33), dermatomyositis (n = 69), systemic sclerosis (n = 55), mixed connective tissue disease (n = 21), microscopic polyangiitis (n = 19), and overlap syndrome (n = 28). Of the 42patients who died during hospitalization, 22 died from CTD-IP, 15 from CTD-IP and pulmonary infection, 2 from pulmonary infection, and 3 from other causes. Age > 65 years and development of pulmonary infections after commencing or intensifying immunosuppressive treatments were identified as risk factors for death during hospitalization after adjusting for covariates. Conclusion. Careful consideration of the benefit - risk balance of immunosuppressive treatment for CTD-IP is indispensable for improving the short-term vital prognosis of these patients.
| Original language | English |
|---|---|
| Pages (from-to) | 609-614 |
| Number of pages | 6 |
| Journal | Modern Rheumatology |
| Volume | 25 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2015 |
Fingerprint
Keywords
- Connective tissue disease
- Immunosuppressive treatments
- Interstitial pneumonia
- Pulmonary infections
- Vital prognosis
ASJC Scopus subject areas
- Rheumatology
Cite this
Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia. / Tanaka, Michi; Koike, Ryuji; Sakai, Ryoko; Saito, Kazuyoshi; Hirata, Shintaro; Nagasawa, Hayato; Kameda, Hideto; Hara, Masako; Kawaguchi, Yasushi; Tohma, Shigeto; Takasaki, Yoshinari; Dohi, Makoto; Nishioka, Yasuhiko; Yasuda, Shinsuke; Miyazaki, Yasunari; Kaneko, Yuko; Nanki, Toshihiro; Watanabe, Kaori; Yamazaki, Hayato; Miyasaka, Nobuyuki; Harigai, Masayoshi.
In: Modern Rheumatology, Vol. 25, No. 4, 2015, p. 609-614.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia
AU - Tanaka, Michi
AU - Koike, Ryuji
AU - Sakai, Ryoko
AU - Saito, Kazuyoshi
AU - Hirata, Shintaro
AU - Nagasawa, Hayato
AU - Kameda, Hideto
AU - Hara, Masako
AU - Kawaguchi, Yasushi
AU - Tohma, Shigeto
AU - Takasaki, Yoshinari
AU - Dohi, Makoto
AU - Nishioka, Yasuhiko
AU - Yasuda, Shinsuke
AU - Miyazaki, Yasunari
AU - Kaneko, Yuko
AU - Nanki, Toshihiro
AU - Watanabe, Kaori
AU - Yamazaki, Hayato
AU - Miyasaka, Nobuyuki
AU - Harigai, Masayoshi
PY - 2015
Y1 - 2015
N2 - Objective. Connective tissue disease-associated interstitial pneumonia (CTD-IP) significantly affects the mortality of patients with CTD. The purpose of the present study is to identify causes and risk factors for death during hospitalization for immunosuppressive treatment of CTD-IP. Methods. A multicenter, retrospective study was conducted that collected data from patients with CTD who had been hospitalized for commencing or intensifying immunosuppressive treatment of CTD-IP using a standardized case report form. Risk factors were identified using the Cox proportional hazard regression model. Results. A total of 322 CTD-IP patients were enrolled with rheumatoid arthritis (n = 84), systemic lupus erythematosus (n = 13), polymyositis (n = 33), dermatomyositis (n = 69), systemic sclerosis (n = 55), mixed connective tissue disease (n = 21), microscopic polyangiitis (n = 19), and overlap syndrome (n = 28). Of the 42patients who died during hospitalization, 22 died from CTD-IP, 15 from CTD-IP and pulmonary infection, 2 from pulmonary infection, and 3 from other causes. Age > 65 years and development of pulmonary infections after commencing or intensifying immunosuppressive treatments were identified as risk factors for death during hospitalization after adjusting for covariates. Conclusion. Careful consideration of the benefit - risk balance of immunosuppressive treatment for CTD-IP is indispensable for improving the short-term vital prognosis of these patients.
AB - Objective. Connective tissue disease-associated interstitial pneumonia (CTD-IP) significantly affects the mortality of patients with CTD. The purpose of the present study is to identify causes and risk factors for death during hospitalization for immunosuppressive treatment of CTD-IP. Methods. A multicenter, retrospective study was conducted that collected data from patients with CTD who had been hospitalized for commencing or intensifying immunosuppressive treatment of CTD-IP using a standardized case report form. Risk factors were identified using the Cox proportional hazard regression model. Results. A total of 322 CTD-IP patients were enrolled with rheumatoid arthritis (n = 84), systemic lupus erythematosus (n = 13), polymyositis (n = 33), dermatomyositis (n = 69), systemic sclerosis (n = 55), mixed connective tissue disease (n = 21), microscopic polyangiitis (n = 19), and overlap syndrome (n = 28). Of the 42patients who died during hospitalization, 22 died from CTD-IP, 15 from CTD-IP and pulmonary infection, 2 from pulmonary infection, and 3 from other causes. Age > 65 years and development of pulmonary infections after commencing or intensifying immunosuppressive treatments were identified as risk factors for death during hospitalization after adjusting for covariates. Conclusion. Careful consideration of the benefit - risk balance of immunosuppressive treatment for CTD-IP is indispensable for improving the short-term vital prognosis of these patients.
KW - Connective tissue disease
KW - Immunosuppressive treatments
KW - Interstitial pneumonia
KW - Pulmonary infections
KW - Vital prognosis
UR - http://www.scopus.com/inward/record.url?scp=84935016185&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84935016185&partnerID=8YFLogxK
U2 - 10.3109/14397595.2014.980384
DO - 10.3109/14397595.2014.980384
M3 - Article
C2 - 25496409
AN - SCOPUS:84935016185
VL - 25
SP - 609
EP - 614
JO - Modern Rheumatology
JF - Modern Rheumatology
SN - 1439-7595
IS - 4
ER -